Proteinuria is one of the most important risk factors for chronic kidney disease (CKD) progression. Approximately 5% to 10% of pediatric nephrotic syndrome is resistant to steroids and other immunosuppressants, and up to one-third of them are caused by monogenic disorders. Blockers of the renin-angiotensin-aldosterone system are considered as the basic treatment for proteinuric CKD. However, these agents often cannot achieve sufficient proteinuria reduction. Recently, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated benefits in reducing proteinuria and improving kidney outcomes in patients with proteinuric CKD with and without type 2 diabetes in adults.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: